Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTSohini MondalThu, July 16, 2026 at 3:18 AM GMT+2 2 min readIncyte Corp_ office sign-by Bo Shen via iStockWith a market cap of around $23 billion, Incyte Corporation (INCY) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics across the United States, Europe, Canada, and Japan. It markets a diverse portfolio of oncology, immunology, and dermatology medicines, including JAKAFI, OPZELURA, and ICLUSIG.The Wilmington, Delaware-based company is set to unveil its fiscal Q2 2026 results before the market opens on Tuesday, Jul. 28. Ahead of this event, analysts expect INCY to report a profit of $1.61 per share, up 22.9% from $1.31 per share in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in three of the past four quarters while missing on another occasion.More News from BarchartNvidia Stock Could Still Soar 140% to Reach $500, Says Wall StreetMU Stock Alert: What to Watch as Micron Takes a Stake in GlobalWafersIBM Stock Just Suffered a Gruesome Massacre, But Algos Likely Sense a Huge Discount HereStop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now!For fiscal 2025, analysts forecast the specialty drugmaker to post EPS of $6.61, an increase of 18.5% from $5.58 in fiscal 2025.www.barchart.comINCY stock has soared 68.6% over the past 52 weeks, outperforming the broader S&P 500 Index's ($SPX) 21.3% gain and the State Street Health Care Select Sector SPDR ETF's (XLV) 19.4% return over the same period. www.barchart.comIncyte shares rose 2.1% on Apr. 28 after the company reported Q1 2026 results that exceeded analyst expectations, driven by strong demand for its cancer therapies. Adjusted EPS came in at $1.81 and revenue increased to $1.27 billion, both surpassing expectations, supported by 7% growth in Jakafi net sales to $757.8 million, which exceeded analyst forecasts. Investor sentiment was also supported by the company's decision to reaffirm its full-year revenue guidance of $4.77 billion - $4.94 billion, although gains were partially tempered by Opzelura sales of $143 million, which, despite 20% year-over-year growth, missed analysts' expectations.Analysts' consensus rating on INCY stock is cautiously optimistic, with a "Moderate Buy" rating overall. Out of 26 analysts covering the stock, opinions include 11 "Strong Buy," and 15 "Holds." As of writing, it is trading above the average analyst price target of $114.87. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.comTerms and Privacy PolicyEU DSA contactPrivacy & Cookie SettingsMore Info